{
    "clinical_study": {
        "@rank": "40252", 
        "arm_group": [
            {
                "arm_group_label": "G238", 
                "arm_group_type": "Experimental", 
                "description": "Five drops into the ear canal twice daily for 14 days"
            }, 
            {
                "arm_group_label": "Clotrimazole", 
                "arm_group_type": "Active Comparator", 
                "description": "Five drops into the ear canal twice daily for 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of G238 for the treatment\n      of otomycosis"
        }, 
        "brief_title": "Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Otomycosis", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years or older.\n\n          -  Clinical diagnosis of otomycosis where topical treatment is indicated.\n\n        Exclusion Criteria:\n\n          -  Other ear diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "230", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993823", 
            "org_study_id": "G238OTIII/11IA01"
        }, 
        "intervention": [
            {
                "arm_group_label": "G238", 
                "description": "Five drops into the ear canal twice daily for 14 days", 
                "intervention_name": "G238", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Clotrimazole", 
                "description": "Five drops into the ear canal twice daily for 14 days", 
                "intervention_name": "Clotrimazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clotrimazole", 
                "Miconazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "contact": {
                "email": "clinicaltrials@salvatbiotech.com", 
                "last_name": "Enrique Jimenez, MD", 
                "phone": "+34933946400", 
                "phone_ext": "470"
            }, 
            "facility": {
                "address": {
                    "city": "Esplugues de Llobregat", 
                    "country": "Spain", 
                    "state": "Barcelona", 
                    "zip": "08950"
                }, 
                "name": "Laboratorios SALVAT, S.A."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Active Treatment-controlled Study Assessing the Safety and Efficacy of G238 Compared to Clotrimazole 1% Otic Solution in Patients With Otomycosis", 
        "other_outcome": {
            "measure": "Mycological study", 
            "safety_issue": "No", 
            "time_frame": "Day 24"
        }, 
        "overall_contact": {
            "email": "clinicaltrials@salvatbiotech.com", 
            "last_name": "Enrique Jimenez, MD", 
            "phone": "+34933946400", 
            "phone_ext": "470"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Federal Commission for Sanitary Risks Protection"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy will be assessed primarily by evaluation of the fungal culture, and the sum of signs and symptom scores (pruritus, otalgia, otorrhea and aural fullness obstruction to be scored as 0=absent; 1= mild; 2=moderate; 3=severe). The primary efficacy variable is the proportion of subjects with a negative culture for fungus, AND a signs and symptom score of \"0\" on Day 24.", 
            "measure": "Clinical and mycological evaluation", 
            "safety_issue": "No", 
            "time_frame": "Day 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993823"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary efficacy variables will include:\nProportion of subjects with signs and symptoms score of \"0\" at each visit.\nProportion of subjects with a negative culture for fungus or presumed eradication on Day 24.\nThe changes in signs and symptoms after two (2) weeks of treatment.\nThe changes in signs/symptoms at Day 24.\nThe mycological study results obtained in the cultures at day 24.\nThe number of patients with clinical cure or improvement at day 14 and 24.", 
            "measure": "Changes in signs/ symptoms", 
            "safety_issue": "No", 
            "time_frame": "2 weeks and 4 weeks"
        }, 
        "source": "Salvat", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Salvat", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}